about
RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infectionProhibitin 2: At a communications crossroadsSerine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibitionSignal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugsPLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cellsInvolvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer.Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.A rapid standardized quantitative microfluidic system approach for evaluating human tear proteins.RAX is required for fly neuronal development and mouse embryogenesis.Phosphoinositide-specific phospholipase C β 1b (PI-PLCβ1b) interactome: affinity purification-mass spectrometry analysis of PI-PLCβ1b with nuclear protein.Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.Nuclear PI-PLCβ1: an appraisal on targets and pathology.Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells.Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells.Cell Cycle Arrest and Apoptosis Induced by Kinamycin F in Human Osteosarcoma Cells.BMP-2 Induced Expression of PLCβ1 That is a Positive Regulator of Osteoblast Differentiation.PI-PLCβ1b affects Akt activation, cyclin E expression, and caspase cleavage, promoting cell survival in pro-B-lymphoblastic cells exposed to oxidative stress.PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation.Prohibitin 2 represents a novel nuclear AKT substrate during all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.Identification of the PKR nuclear interactome reveals roles in ribosome biogenesis, mRNA processing and cell division.Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress.eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C βI.Intolerant contact lens wearers exhibit ocular surface impairment despite 3 months wear discontinuation.PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation.Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells.Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells.Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes.Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf.Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells.A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX.Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.A role for PKR in hematologic malignancies.MiRNA-210: A Current Overview.A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.A role for PLCβ1 in myotonic dystrophies type 1 and 2Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells
P50
Q24671766-C1240DB6-F04E-4F64-AE3E-F9B114BA45A1Q26825374-B254FC7A-6E08-4BCF-9512-06EFAF6B73A6Q28276027-64EF9BCC-6E34-4266-82FC-40DEB0DAFB69Q28609063-3A7B1FED-FB5E-45F0-B2FB-277328298657Q34100915-BE1BBC78-337C-4937-8C07-B2BE6BD6D1C0Q34184917-D199D850-6701-496E-A477-9E0EDF4905FDQ35063894-AFA9780F-D8EB-434B-8382-06196BB63E59Q35077778-E8E288B0-1F14-4580-8405-B6ECCC27C9AAQ35166852-9CED0FA7-7E34-4210-A173-C7E1454C64A6Q36350426-5F569E2E-396B-4F00-9544-C4C341F013B9Q36925446-CF0E6751-0A89-4E21-B72D-07554CBE91EEQ37072873-0E11666D-4367-481D-BAAE-E88CDD513ABEQ37138122-AF60D349-34CD-4611-BC3F-0351B9DE8C03Q38167978-0E70294E-A4D3-492D-8B86-AE14A0E59EBAQ38311147-B58A9DCE-53FA-4536-B05E-283B5EFFEA28Q38311150-A5815BFF-52DC-4BA2-AB1F-86C8C4F2B5A0Q38696478-F32B5C5B-C8E0-46BA-B42B-98F55C96FE22Q38848695-97A906E6-1D57-431F-A1F3-8F00B5496C7CQ38924298-FBCA2C53-0C2A-4447-985C-66998EA42E10Q38962513-88FFC35B-CD4B-4742-AA38-9BD4CAE1C062Q39024464-04FA7084-0950-423D-AFA2-C67A96B6FABBQ39042417-9DAA837B-DB23-4381-80B6-512256EF1F66Q39632814-A8DBC63C-FEBA-43E6-876F-A4BA04E20DF5Q39647951-3E151D46-68A4-4BB1-B6C3-14EB79A7FF39Q39695424-3BA424B1-EF03-48C7-A7D5-8A2AC6FA5F6BQ39841023-59BAF6B5-79B7-4198-8D52-816242E40AFEQ40574598-4281EA3D-C54B-4473-90D1-A1E70C79969DQ40581448-FA0FB841-236F-451B-8B96-55BE9672DFD3Q40666602-FCBBD019-C70E-45A3-9D1E-C788113784F0Q40802206-AABDD00A-602D-4E49-BD2B-0ED4FF84672EQ40877375-A8A8B06C-9EF1-496F-91C0-4814EB855EB2Q40896676-D23F58EE-86B2-4B44-BB71-4C439ACBC3F5Q43517016-B1530DB2-7FC1-4FC8-B863-5DC131A36B8AQ44419395-19CDAA02-77FA-4277-B142-F69D64319D4DQ44452162-6C34A82C-E9A0-4E52-8F42-E6E443BE280CQ46035657-4D44D57A-9173-447E-BE17-FE06B8D2FB1BQ47350692-F6D7C822-40C0-45CA-A0A1-890699E20820Q47696147-5531C939-F596-4022-8548-CC55C3A97E53Q56981228-0D6891F6-A216-43A6-942A-1832843D1484Q57369846-E2764DF2-170A-463C-97CA-1BA2941D0DE3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William Blalock
@ast
William Blalock
@en
William Blalock
@es
William Blalock
@nl
type
label
William Blalock
@ast
William Blalock
@en
William Blalock
@es
William Blalock
@nl
altLabel
Blalock WL
@en
William L Blalock
@en
prefLabel
William Blalock
@ast
William Blalock
@en
William Blalock
@es
William Blalock
@nl
P1053
C-6959-2019
P106
P31
P496
0000-0002-8045-4840